Payment overview · 2025
General Payments
$1,073.73
79 reported records · 11 companies
Healthcare provider profile · identity verified
Dean Moscovic, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CLARKSTON, MI · NPI 1952309718
Verified facts
What the public records show
CMS Open Payments records show Dean Moscovic, DO received $1,073.73 in general payments during 2025 across 79 reported records.
PFIZER INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $253.09 | 23.6% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.92 | 21.2% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.62 | 18.1% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.12 | 13.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.44 | 11.7% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.61 | 3.0% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $28.23 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.56 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.95 | 1.5% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $15.49 | 1.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.70 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,073.73 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $235.57 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $219.18 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $196.28 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $148.41 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.12 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.95 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.95 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $102.88 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $102.88 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.98 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.88 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $38.51 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| NOVASURE Normalized: novasure |
Device | Hologic Sales and Service, LLC | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.96 | 7 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $7.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 179 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
179 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 649 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 147 |
| Alprazolam | Alprazolam | 526 | 98 |
| Omeprazole | Omeprazole | 499 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 482 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 122 |
| Losartan Potassium | Losartan Potassium | 402 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 87 |
| Gabapentin | Gabapentin | 291 | 59 |
| Lisinopril | Lisinopril | 282 | 74 |
| Furosemide | Furosemide | 270 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 68 |
| Oxycodone Hcl | Oxycodone Hcl | 236 | 30 |
| Montelukast Sodium | Montelukast Sodium | 209 | 58 |
| Simvastatin | Simvastatin | 205 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 60 |
| Carvedilol | Carvedilol | 199 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 53 |
| Metformin Hcl Er | Metformin Hcl | 193 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 62 |
| Eliquis | Apixaban | 180 | 38 |
| Mounjaro | Tirzepatide | 179 | 30 |
| Meloxicam | Meloxicam | 171 | 49 |
| Ozempic | Semaglutide | 159 | 32 |
| Azithromycin | Azithromycin | 155 | 106 |
| Metformin Hcl | Metformin Hcl | 146 | 38 |
| Trazodone Hcl | Trazodone Hcl | 143 | 36 |
| Ibuprofen | Ibuprofen | 142 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 38 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 140 | 21 |
| Potassium Chloride | Potassium Chloride | 140 | 41 |
| Diazepam | Diazepam | 139 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 25 |
| Tramadol Hcl | Tramadol Hcl | 130 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 35 |
| Jardiance | Empagliflozin | 122 | 26 |
| Fluconazole | Fluconazole | 120 | 36 |
| Sertraline Hcl | Sertraline Hcl | 116 | 33 |
| Allopurinol | Allopurinol | 113 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 44 |
| Lorazepam | Lorazepam | 108 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 26 |
| Baclofen | Baclofen | 104 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 29 |
| Prednisone | Prednisone | 101 | 46 |
| Clonazepam | Clonazepam | 100 | 18 |
| Methylprednisolone | Methylprednisolone | 95 | 75 |
| Bupropion Xl | Bupropion Hcl | 94 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 21 |
| Glimepiride | Glimepiride | 89 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 23 |
| Ondansetron Odt | Ondansetron | 85 | 24 |
| Celecoxib | Celecoxib | 84 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 18 |
| Sucralfate | Sucralfate | 82 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 81 | suppressed |
| Amoxicillin | Amoxicillin | 80 | 32 |
| Fentanyl | Fentanyl | 80 | 11 |
| Pregabalin | Pregabalin | 78 | 15 |
| Aripiprazole | Aripiprazole | 77 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 12 |
| Donepezil Hcl | Donepezil Hcl | 76 | 24 |
| Ezetimibe | Ezetimibe | 76 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 70 | suppressed |
| Valsartan | Valsartan | 70 | 17 |
| Famotidine | Famotidine | 66 | 16 |
| Valacyclovir | Valacyclovir Hcl | 66 | 28 |
| Memantine Hcl | Memantine Hcl | 64 | 15 |
| Finasteride | Finasteride | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Mupirocin | Mupirocin | 56 | 23 |
| Atenolol | Atenolol | 55 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 37 |
| Methenamine Hippurate | Methenamine Hippurate | 53 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 47 |
| Cephalexin | Cephalexin | 52 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 16 |
| Morphine Sulfate | Morphine Sulfate | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 32 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 19 |
| Novolog Flexpen | Insulin Aspart | 50 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 49 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 14 |
| Methocarbamol | Methocarbamol | 48 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 13 |
| Fenofibrate | Fenofibrate | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 12 |
| Nystatin | Nystatin | 44 | 27 |
| Spironolactone | Spironolactone | 44 | 15 |
| Cefdinir | Cefdinir | 43 | 30 |
| Meclizine Hcl | Meclizine Hcl | 42 | 13 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Levofloxacin | Levofloxacin | 40 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Colchicine | Colchicine | 34 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Felodipine Er | Felodipine | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 24 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Trospium Chloride | Trospium Chloride | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 11 |
| Estradiol | Estradiol | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Naproxen | Naproxen | 20 | 11 |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Paliperidone Er | Paliperidone | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 11 |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Toviaz | Fesoterodine Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,073.73 · 79 records | PFIZER INC. | BREZTRI, ELIQUIS, Grastek, INCEPTIV, JARDIANCE, MOUNJARO, NOVASURE, NURTEC ODT, OTEZLA, Odactra, Ozempic, PAXLOVID, QULIPTA, REPATHA, Ragwitek, Rybelsus, SYNTHROID, Symbravo, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error